Monoclonal Antibodies Market Size - By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By End-use, Global Forecast (2023-2032)

Monoclonal Antibodies Market Size

Monoclonal Antibodies Market size was valued at more than USD 186.6 billion in 2022 and will progress tremendously to reach over USD 609 billion by 2032 at 12.5% CAGR attributing to the increasing prevalence of chronic and infectious diseases, growing research and development activities, high rate of adoption of monoclonal antibodies in the U.S. and Europe
 

Monoclonal antibodies (mAbs) are referred to the category of proteins having ability to bind to specific cells. These are identical immunoglobulins derived from a single B-cell that recognizes unique binding site on antigen. Due to its specificity to unique epitopes, mAbs are being increasingly used for diagnostic and therapeutic applications for several disease. Currently, large number of monoclonal antibodies are available in the market to treat cancer, cardiovascular diseases, autoimmune diseases, blood disorders, and infectious diseases among others.
 

COVID-19 Impact

The COVID-19 virus outbreak has positively influenced the monoclonal antibodies industry development. Sudden upsurge in number of patients associated with COVID-19 and mortality risk associated with the infection has driven need for effective therapies. Adding to this, several industry players such as Eli Lilly and company and GlaxoSmithKline were continuously involved in development of innovative monoclonal antibodies for prevention and treatment of COVID-19 virus due to its potential to combat disease burden. Moreover, large number of ongoing clinical trials to develop novel drug therapy as well as wide range of product approvals for emergency use in COVID-19 treatment.
 

Monoclonal Antibodies Driving Factors

Rapid progress in prevalence of chronic infectious and rare diseases is a prime factor driving monoclonal antibodies market revenue expansion. For instance, according to the World Health Organization, in 2020, around 10 million people died due to cancer worldwide. This has proportionated one third deaths due to cancer in respective year. Additionally, significant number of monoclonal antibodies are indicated for cancer treatment therapies that has offered revenue progression opportunities to the market. Moreover, extensive product pipeline with potential effective therapies catering to such diverse range of diseases will result in market expansion. Thus, with high product approval rate, contributing to increasing accessibility.
 

Monoclonal Antibodies Market Analysis

Based on type, the monoclonal antibodies market is classified into fully human, humanized, chimeric, and other types. Fully human monoclonal antibodies segment dominated the monoclonal antibodies industry with 50.8% market share in 2022. Increase in number of product approvals and drug launches of fully human monoclonal antibodies has positively impacted the segment gains by 2032. Integration of advanced technologies has enabled faster discovery and product development. The large-scale production of fully human monoclonal antibodies is cost-effective and more feasible due to the advances in biotechnology and cell culture techniques. This will further lead to shift in focus towards the use of fully human mAbs for immunotherapeutic applications. The use of fully human monoclonal antibodies reduces the risk of cross-reactivity with antigens in non-human species, while studying disease in animal models.
 

Based on application, the monoclonal antibodies market is classified oncology, autoimmune diseases, infectious diseases, and other applications. Oncology segment is anticipated to proceed at 12.6% CAGR by 2032. Monoclonal antibodies are proven effective for targeted treatment of cancer. Moreover, numerous monoclonal antibodies have multiple applications offering advantage of single mAb to target different types of cancers. Moreover, to cater increasing disease burden, key market players are adopting developmental activities.
 

Based on end-use, the monoclonal antibodies market based on end-use is segmented as hospitals, specialty centres, and other end-uses. Hospitals segment was valued around USD 79.6 billion in 2022 owing to increase in number of patient hospitalizations for range of chronic diseases. Hospitals are well-equipped to manage chronic diseases and other complex medical conditions, and the availability of advanced drug therapies in hospitals has driven patient preference. Highly skilled professionals providing specialty treatments such as cancer and autoimmune diseases drives the product demand in hospitals. Moreover, reimbursement policies for high-cost therapies in hospitals influence the patient visits.
 

North America monoclonal antibodies market accounted for more than 48.8% in 2022 owing to the strong presence of key business players and number of product approvals. Enhanced product adoption for effective disease treatment propels demand for monoclonal antibodies in the regional business. Moreover, increasing R&D expenditure by organizations and support for cancer research by the government has allowed discovery of novel monoclonal antibodies therapeutics. Additionally, expansion of manufacturing capacities boosts product availability and sales. Moreover, increasing number of product approvals in the U.S. and Canada stimulates the regional industry progression. Well-developed healthcare infrastructure has increased treatment accessibility to population.
 

Monoclonal Antibodies Market Share

Some of notable key players operating in the monoclonal antibodies market including

• AbbVie Inc.
• F. Hoffmann-La Roche
• Amgen Inc.
• Bristol Myers Squibb
• Johnson & Johnson
• Merck & Co., Inc.
• Regeneron Pharmaceuticals Inc.
• AstraZeneca
• Eli Lilly and Company
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Novartis AG 
   

Monoclonal Antibodies Industry News:

• In June 2021, Amgen, Inc. entered in agreement with Kyowa Kirin Co. Ltd., to develop and commercialize KHK4083, a fully human monoclonal antibody for the treatment of atopic dermatitis. Such partnerships have helped the company in business expansion.
   
• In May 2021, Roche India announced the Emergency Use Authorisation (EUA) for its antibody cocktail by the Central Drugs Standards Control Organisation (CDSCO). This authorization has enabled the company to broaden product accessibility in the country.
   

The monoclonal antibodies market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Type

• Fully human
• Humanized
• Chimeric
• Other types 

By Application

• Oncology
• Autoimmune diseases
• Infectious diseases
• Other applications

By End-use

• Hospitals
• Specialty centers
• Other end-uses

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Singapore
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Egypt
  • Kuwait
  • Rest of Middle East & Africa